Published in Int J Cancer on January 18, 1999
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 2.96
Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res (1987) 2.85
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys (1986) 1.84
Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res (1999) 1.79
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res (2001) 1.75
The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys (1989) 1.71
Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer (1985) 1.57
The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys (1987) 1.48
Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer (1985) 1.47
An assessment of 31P MRS as a method of measuring pH in rat tumours. NMR Biomed (1993) 1.45
Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer (2000) 1.44
Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res (2001) 1.32
Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer (1999) 1.30
Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. Br J Radiol (2003) 1.27
Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res (1989) 1.20
Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer (1989) 1.19
Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol (2008) 1.19
Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res (1998) 1.19
The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res (1995) 1.18
Tumour blood flow changes induced by application of electric pulses. Eur J Cancer (1999) 1.17
Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer (1993) 1.17
Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res (2000) 1.11
Possible mechanisms for intermittent blood flow in the murine SCCVII carcinoma. Int J Radiat Biol (1991) 1.10
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 1.09
Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol (1998) 1.09
Kinetic modeling of hyperpolarized (13)C pyruvate metabolism in tumors using a measured arterial input function. Magn Reson Med (2012) 1.09
Targeting gene therapy to cancer: a review. Oncol Res (1997) 1.08
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer (2010) 1.07
Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol (1996) 1.06
Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer (1998) 1.05
Intermittent blood flow in the KHT sarcoma--flow cytometry studies using Hoechst 33342. Br J Cancer (1990) 1.04
Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer (2001) 1.03
Measurement of tumor oxygenation: in vivo comparison of a luminescence fiber-optic sensor and a polarographic electrode in the p22 tumor. Radiat Res (2001) 1.02
Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res (1987) 1.01
The use of ketamine plus diazepam anaesthesia to increase the radiosensitivity of a C3H mouse mammary adenocarcinoma in hyperbaric oxygen. Br J Radiol (1984) 1.01
Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer (2000) 0.99
Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res (2001) 0.99
Limitations of the reporter green fluorescent protein under simulated tumor conditions. Cancer Res (2001) 0.99
Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration. Int J Radiat Oncol Biol Phys (1989) 0.98
An automatic algorithm for the segmentation and morphological analysis of microvessels in immunostained histological tumour sections. J Microsc (2010) 0.98
Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer (1995) 0.98
The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res (2001) 0.97
Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. Br J Cancer (1990) 0.97
Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed (1999) 0.97
Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles. Int J Radiat Biol Relat Stud Phys Chem Med (1983) 0.97
Distribution of Photofrin between tumour cells and tumour associated macrophages. Br J Cancer (1991) 0.96
Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res (1990) 0.96
The energy metabolism of RIF-1 tumours following hydralazine. Radiother Oncol (1990) 0.96
Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol (1999) 0.95
Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br J Cancer (2000) 0.95
Ischaemia induced cell death in tumors: importance of temperature and pH. Int J Radiat Oncol Biol Phys (1994) 0.94
The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours. Br J Cancer (1995) 0.94
Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res (1997) 0.94
Transient perfusion and radiosensitizing effect after nicotinamide, carbogen, and perflubron emulsion administration. Radiother Oncol (1996) 0.93
The effect of hypoxia and low pH on the cytotoxicity of chlorambucil. Int J Radiat Oncol Biol Phys (1992) 0.93
The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. Radiother Oncol (1994) 0.93
Characterisation of tumour blood flow using a 'tissue-isolated' preparation. Br J Cancer (1994) 0.93
Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide. Cancer Res (1995) 0.93
Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther (2000) 0.93
Cell sorting with Hoechst or carbocyanine dyes as perfusion probes in spheroids and tumors. Methods Cell Biol (1990) 0.92
Enhancement of chlorambucil cytotoxicity by combination with flavone acetic acid in a murine tumour. Anticancer Res (1994) 0.92
Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. Int J Radiat Oncol Biol Phys (1994) 0.92
The influence of microenvironment on the cytotoxicity of TNF [symbol: see text] vitro. Int J Radiat Oncol Biol Phys (1994) 0.91
Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug. Anticancer Drug Des (1998) 0.91
The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Br J Cancer (1997) 0.91
Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions. Mol Cancer Ther (2001) 0.90
The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor. Int J Radiat Oncol Biol Phys (1986) 0.90
Measuring the velocity of fluorescently labelled red blood cells with a keyhole tracking algorithm. J Microsc (2008) 0.90
Tumour radiosensitization by high-oxygen-content gases: influence of the carbon dioxide content of the inspired gas on PO2, microcirculatory function and radiosensitivity. Int J Radiat Oncol Biol Phys (1998) 0.90
Effect of angiotensin II on intermittent tumour blood flow and acute hypoxia in the murine SCCVII carcinoma. Eur J Cancer (1991) 0.89
Photofrin uptake by murine macrophages. Cancer Res (1991) 0.89
Measurement of tumor oxygenation: a comparison between polarographic needle electrodes and a time-resolved luminescence-based optical sensor. Radiat Res (1997) 0.89
The combined measurement of blood flow and metabolism in RIF-1 tumours in vivo. A study using H2 flow and 31P NMR spectroscopy. NMR Biomed (1990) 0.88
The influence of vasoactive agents on the perfusion of tumours growing in three sites in the mouse. Int J Radiat Biol (1991) 0.88
The effects of hyperoxic and hypercarbic gases on tumour blood flow. Br J Cancer (1999) 0.88
Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol (1994) 0.88
Modification of tumor blood flow: current status and future directions. Semin Radiat Oncol (1998) 0.87
The influence of nitric oxide on tumour vascular tone. Acta Oncol (1995) 0.87
Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer Suppl (1996) 0.87
Metabolic and clonogenic consequences of ischaemia reperfusion insult in solid tumours. Exp Physiol (1997) 0.87
Inhibition of intracellular pH control and relationship to cytotoxicity of chlorambucil and vinblastine. Br J Cancer Suppl (1996) 0.86
Effect of carbogen breathing on tumour microregional blood flow in humans. Radiother Oncol (1996) 0.86
Nitric oxide in biological fluids: analysis of nitrite and nitrate by high-performance ion chromatography. J Chromatogr A (1995) 0.85
Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT). Br J Cancer (1986) 0.85
Resistance to flow through tissue-isolated transplanted rat tumours located in two different sites. Br J Cancer (1993) 0.85
The comparative effects of the NOS inhibitor, Nomega-nitro-L-arginine, and the haemoxygenase inhibitor, zinc protoporphyrin IX, on tumour blood flow. Int J Radiat Oncol Biol Phys (1998) 0.85